Systematic review with network meta-analysis: The comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 7, 2015, Pages 624-635

  Zhu, G Q ^a,b   Shi, K Q ^a,b   Huang, S ^a,b   Wang, L R ^a,b   Lin, Y Q ^a,b   Huang, G Q ^a,b   Chen, Y P ^a,b   Braddock, M ^c   Zheng, M H ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; AMMONIA; ASPARTIC ACID; BRANCHED CHAIN AMINO ACID; DISACCHARIDE; NEOMYCIN; ORNITHINE; RIFAXIMIN; DIPEPTIDE; GASTROINTESTINAL AGENT; ORNITHYLASPARTATE; RIFAMYCIN;

ADVERSE OUTCOME; AMMONIA BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEPATIC ENCEPHALOPATHY; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; BLOOD; MENTAL HEALTH;

AMINO ACIDS, BRANCHED-CHAIN; AMMONIA; DIPEPTIDES; DISACCHARIDES; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; MENTAL HEALTH; NEOMYCIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMYCINS;

EID: 84926220931     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13122     Document Type: Review

References (50)

1. Dhiman RK, Kurmi R, Thumburu KK, et al,. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010; 55: 2381-90.
2. de Melo RT, Charneski L, Hilas O,. Rifaximin for the treatment of hepatic encephalopathy. Am J Health Syst Pharm 2008; 65: 818-22.
3. Sheasgreen C, Lu L, Patel A,. Pathophysiology, diagnosis, and management of hepatic encephalopathy. Inflammopharmacology 2014; 22 (6): 319-26.
4. Fichet J, Mercier E, Genee O, et al,. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care 2009; 24: 364-70.
5. Sheasgreen C, Lu L, Patel A,. Pathophysiology, diagnosis, and management of hepatic encephalopathy. Inflammopharmacology 2014; 22: 319-26.
6. Nusrat S, Khan MS, Fazili J, Madhoun MF,. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol 2014; 20: 5442-60.
7. Vilstrup H, Amodio P, Bajaj J, et al,. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, MD) 2014; 60: 715-35.
8. Paik YH, Lee KS, Han KH, et al,. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46: 399-407.
9. Gluud LL, Dam G, Borre M, et al,. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis 2013; 28: 221-5.
10. Bai M, Yang Z, Qi X, Fan D, Han G,. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013; 28: 783-92.
11. Tarao K, Ikeda T, Hayashi K, et al,. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990; 31: 702-6.
12. Zeneroli ML, Avallone R, Corsi L, Venturini I, Baraldi C, Baraldi M,. Management of hepatic encephalopathy: role of rifaximin. Chemotherapy 2005; 51 (Suppl. 1): 90-5.
13. Lawrence KR, Klee JA,. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008; 28: 1019-32.
14. Eltawil KM, Laryea M, Peltekian K, Molinari M,. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012; 18: 767-77.
15. Rose C, Michalak A, Pannunzio P, et al,. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13: 147-57.
16. Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO,. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000; 47: 571-4.
17. Kircheis G, Nilius R, Held C, et al,. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology (Baltimore, MD) 1997; 25: 1351-60.
18. Stauch S, Kircheis G, Adler G, et al,. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998; 28: 856-64.
19. Poo JL, Gongora J, Sanchez-Avila F, et al,. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 2006; 5: 281-8.
20. Gluud LL, Dam G, Borre M, et al,. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr 2013; 143: 1263-8.
21. Song F, Altman DG, Glenny AM, Deeks JJ,. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472.
22. Ades AE, Sculpher M, Sutton A, et al,. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24: 1-19.
23. Sutton A, Ades AE, Cooper N, Abrams K,. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26: 753-67.
24. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-41.
25. Riordan SM, Williams R,. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337: 473-9.
26. Higgins JP, Altman DG, Gotzsche PC, et al,. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
27. Bowden J, Tierney JF, Copas AJ, Burdett S,. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol 2011; 11: 41.
28. Jansen JP, Fleurence R, Devine B, et al,. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011; 14: 417-28.
29. Lumley T,. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-24.
30. Dias S, Welton NJ, Caldwell DM, Ades AE,. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010; 29: 932-44.
31. Whitlock RP, Chan S, Devereaux PJ, et al,. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J 2008; 29: 2592-600.
32. Abid S, Jafri W, Mumtaz K, et al,. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak 2011; 21: 666-71.
33. Ahmad I, Khan AA, Alam A, et al,. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. J Coll Physicians Surg Pak 2008; 18: 684-7.
34. Atterbury CE, Maddrey WC, Conn HO,. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398-406.
35. Conn HO, Leevy CM, Vlahcevic ZR, et al,. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72 (4 Pt 1): 573-83.
36. Di Piazza S, Gabriella Filippazzo M, Valenza LM, et al,. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991; 23: 403-7.
37. Marchesini G, Dioguardi FS, Bianchi GP, et al,. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11: 92-101.
38. Mas A, Rodes J, Sunyer L, et al,. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-8.
39. Miglio F, Valpiani D, Rossellini SR, Ferrieri A,. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997; 13: 593-601.
40. Raza MA, Bhatti RS, Akram J,. Effect of rectal lactulose administration with oral therapy on time to recovery from hepatic encephalopathy: a randomized study. Ann Saudi Med 2004; 24: 374-7.
41. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C,. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003; 49: 53-62.
42. Wahren J, Denis J, Desurmont P, et al,. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study Hepatology (Baltimore, MD) 1983; 3: 475-80.
43. Jiang L, Yang KH, Guan QL, Chen Y, Zhao P, Tian JH,. Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis. J Clin Gastroenterol 2014; doi: 10.1097/MCG.0000000000000212.
44. Parekh PJ, Shams R, Oldfield ECIB, Nicholas JJ, Johnson DA,. Computed tomography colonography: ready for prime time for colon cancer screening? J Clin Gastroenterol 2014; 48: 745-51.
45. Xiong X, Zhao Y, Tang F, et al,. Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis. eLife 2014; 3: e02236.
46. Bucci L, Palmieri GC,. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13: 109-18.
47. Pedretti G, Calzetti C, Missale G, Fiaccadori F,. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991; 23: 175-8.
48. Jiang Q, Jiang XH, Zheng MH, Chen YP,. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2009; 24: 9-14.
49. Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY,. Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis. Gastroenterol Res Pract 2013; 2013: 236963.
50. Patidar KR, Bajaj JS,. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 2013; 28: 307-12.